The skin gateway
to the Immune System

What's New ?

July, 17 2014

DBV Technologies Completes last "food challenge" visit of last Peanut-Allergic patient in VIPES Phase IIb Clinical Study

  • VIPES is the largest clinical study designed to assess efficacy and safety of Viaskin® Peanut epicutaneous immunotherapy (EPITTM) of peanut allergy
  • DBV confirms it will report VIPES 12-month topline results in October 2014


May, 14 2014

Investor Day - New York City USA

  • Wednesday May 21st, 2014
          at 8.30am (US Time)
                2.30pm (CET)


A revolutionary approach in allergy treatment

11 to 26 million people suffer from food allergy in Europe while at the global level, the estimate is 220 to 500 million people. 3 to 5% of Americans suffer from food allergies and the prevalence of peanut allergy in children has almost quadrupled from 1997 to 2008…

EPIT Method Video

Missing flash plugin. Please download the latest Adobe Flash Player:
Get Adobe Flash Player

A short animation film explaining how DBV uses the Epicutaneous Immunotherapy with its VIASKIN patch to desensitize allergic patients

Legal Mention

CNIL number: 1544201 v 0

DBV technologies - siège social
Green Square - Bâtiment D
80/84 rue des Meuniers
92220 Bagneux
Phone: +33 (0)1 55 42 78 78
Fax: +33 (0)1 43 26 10 83

SIRET: 441772522 00013
RCS: Nanterre

Executive editor: Pierre-Henri Benhamou

Hosting service: OVH

Design : l’enchanteur